Overview

Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

Status:
RECRUITING

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

Multicentre, open-label, single arm phase II study for patients with PM previously treated by immunotherapy and standard chemotherapy. 38 patients will be given second or third-line treatment with ivonescimab 20mg/kg every 3 weeks. An estimated 38 patients will be enrolled in approximately 20 centres. Patients will be treated for a maximum of 2 years, until disease progression, unacceptable toxicity, withdrawal of consent or another discontinuation criterion is met. The null hypothesis is disease control rate (DCR) at 12 weeks 30%. The alternative hypothesis is DCR 55% at 12 weeks.

Phase:

PHASE2

Details

Lead Sponsor:

Intergroupe Francophone de Cancerologie Thoracique

Collaborator:

Summit Therapeutics